Comparing IVF/ICSI Cycle Outcomes of Post Ovulation Ovarian Stimulation Protocol With Elonva Without GnRH Antagonist to Follicular Phase Day 2 Stimulation Fixed Day 5 Antagonist Protocol

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-38
SponsorART Fertility Clinics LLC

About this trial

There are several approaches to the timing of antagonist administration in IVF/ICSI cycles. The primary goal is indeed to prevent premature ovulation, which could jeopardize the success of the cycle There is an emerging concept that suggests that the progesterone produced by the corpus luteum (formed after ovulation) might be sufficient to prevent further ovulation, obviating the need for antagonist or exogenous progesterone administration. This hypothesis relies on the natural regulatory mechanisms of the menstrual cycle to maintain a progesterone-dominated environment post-ovulation. We hypothesized that this approach would minimize treatment costs /burden without having an impact on the outcome.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 to 38 years old.

Normal Menstrual cycle of 25-35 days.

Body Weight 60to90 kg

AMH>1.3 - <3 ng/m (Ferraretti and Gianaroli, 2014; Calzada et al., 2019) an antral follicle count (AFC) of >5 on menstrual cycle days 2-3,

Disqualifiers

History of premature ovulation

Azoospermia

PCOS

Endometriosis AFS ¾

Trial population

Expected normal responder patients who undergo IVF/ICSI+PGT-A at ART Fertility Clinics Dubai \& Abu Dhabi are willing to participate in the study.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

  • Ovarian stimulation with menstruation or after ovulation

    Other intervention

    Ovarian stimulation with menstruation or after ovulation

Treatment groups

252 Participants
are divided into 2 treatment groups
Group A: Group A: - Follicular phase start of ovarian stimulation with Elonva1 intervention
Group B: Group B: One day after the Positive LH kit test at home: E2 P4 LH FSH,BHCG1 intervention

Trial outcomes

Primary outcomes

1

Evaluate the Oocyte maturity, Fertilization rate, Blastulation rate, quality Euploidy rate, Premature ovulation rate, Number of injections used and costs

Time frame
From enrollment to the end of treatment at 8 weeks

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: